Bicycle Therapeutics plc (BCYC) News

Bicycle Therapeutics plc (BCYC): $22.69

0.19 (+0.84%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add BCYC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#321 of 356

in industry

Filter BCYC News Items

BCYC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BCYC News Highlights

  • For BCYC, its 30 day story count is now at 2.
  • Over the past 14 days, the trend for BCYC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest BCYC News From Around the Web

Below are the latest news stories about BICYCLE THERAPEUTICS PLC that investors may wish to consider to help them evaluate BCYC as an investment opportunity.

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

CAMBRIDGE, England & BOSTON, December 14, 2023--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, is today hosting a Research & Development (R&D) Day for investors and analysts in New York to provide clinical updates for BT8009, BT7480 and BT5528, and an overview of the company’s strategy and pipeline opportunities. The company will also highlight the broad capabi

Yahoo | December 14, 2023

Bicycle Therapeutics to Host R&D Day on December 14

CAMBRIDGE, England & BOSTON, November 30, 2023--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14. The event will take place in New York City from 8 a.m. to 12 p.m. Eastern Time and will be simultaneously webcast.

Yahoo | November 30, 2023

Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Just Trimmed Their Revenue Forecasts By 13%

One thing we could say about the analysts on Bicycle Therapeutics plc ( NASDAQ:BCYC ) - they aren't optimistic, having...

Yahoo | November 7, 2023

Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D Day

Company's cash and cash equivalents stand at $572.1 million as of September 30, 2023

Yahoo | November 2, 2023

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

CAMBRIDGE, England & BOSTON, November 02, 2023--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.

Yahoo | November 2, 2023

‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 Stocks

The last few months have been tough for investors, as stocks have mostly been falling since mid-summer. To wit, the S&P 500, which peaked at the end of July, is down close to 8% from that high. The headwinds behind these losses are well-known: stubborn inflation, the Fed’s persistence in sticking to a high-interest-rate, tight-money policy in response, a worsening geopolitical situation and related rising oil prices, increasing bond yields, and the uncertainty of an upcoming election; it would b

Yahoo | November 2, 2023

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, England & BOSTON, October 30, 2023--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in November:

Yahoo | October 30, 2023

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

CAMBRIDGE, England & BOSTON, October 19, 2023--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that BT8009, the company’s lead investigational therapy in development to treat metastatic bladder (urothelial) cancer, has been selected to participate in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program re

Yahoo | October 19, 2023

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ: BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle’s board of directors, he is also a non-executive director of Alchemab Thera

Yahoo | October 19, 2023

An excellent week for Bicycle Therapeutics plc's (NASDAQ:BCYC) institutional owners who own 64% as one-year returns inch higher

Key Insights Given the large stake in the stock by institutions, Bicycle Therapeutics' stock price might be vulnerable...

Yahoo | October 7, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!